Recently, pro-PrP has been pinpointed as potential therapeutic target to reduce melanoma metastasis in vitro and in vivo, using a peptide that inhibited GPI–PSS of pro-PrP and some of its interacting partners [62]. Here, PRNP is linked to melanoma.